Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Carcinoma, Basal Cell 2Melanoma 1

Interventions

pembrolizumab 604Carboplatin 372Paclitaxel 282Cisplatin 267Gemcitabine 252Pemetrexed 193Bevacizumab 190Docetaxel 185Nivolumab 181Injections 167Cyclophosphamide 147atezolizumab 138Fluorouracil 133Capecitabine 133Oxaliplatin 132Dexamethasone 127Fulvestrant 113durvalumab 112130-nm albumin-bound paclitaxel 110fludarabine 101Cetuximab 100Leucovorin 97Rituximab 94venetoclax 90Lenalidomide 83enzalutamide 77Prednisone 76Azacitidine 74Irinotecan 72Ipilimumab 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × daromun × 1 year × Clear all
NCT07227350 2026-06-02

L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)

Philogen S.p.A.

Phase 2 Recruiting
180 enrolled
Dermatologic

Carcinoma, Basal Cell

NCT07227870 2026-03-09

L19IL2/TNF in Patients With Basal Cell Carcinoma

Philogen S.p.A.

Phase 2 Not yet recruiting
92 enrolled
Dermatologic

Carcinoma, Basal Cell

NCT03567889 2025-12-17

NeoDREAM

Philogen S.p.A.

Phase 3 Recruiting
186 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡